XIENCE V demonstrated

Related by string. * Xience : XIENCE V Everolimus Eluting . XIENCE V drug eluting . XIENCE V PROMUS Stent . XIENCE V Stent System / vs . Vs . VD . VS : b v * . V CAST Music . Microsoft Hyper V . overturn Roe v. Wade / demon strated . demon strating . Demonstrating . demonstrating : demonstrating knives mops . demonstrated statistically significant . demonstrated clinically meaningful * *

Related by context. All words. (Click for frequent words.) 74 paclitaxel eluting stents 73 binary restenosis 71 TAXUS p value 70 XIENCE V PROMUS Stent 70 nondiabetic patients 70 diameter stenosis 70 mm Stent 69 MACCE 69 angiographic outcomes 69 symptomatic VTE 69 Operative mortality 69 TAXUS Express Stent 69 events MACE 69 reinfarction 69 morphometric vertebral fractures 69 definite stent thrombosis 69 PLX STROKE targeting 68 ischemia driven 68 everolimus eluting stents 68 non valvular atrial 68 XIENCE V vs. 68 angiographic restenosis 67 repeat revascularization 67 Taxus Stent 67 Myocardial Infarction Study 67 unstable angina pectoris 67 KRAS mutations occur 67 mg BID dose 66 death reinfarction 66 #.#/#.# mmHg [001] 66 postintervention 66 underwent resection 66 achieved ACR# 66 NYHA Class II 66 prespecified secondary 66 ischemic cardiomyopathy 66 ipsilateral stroke 66 Target Lesion Revascularization TLR 65 systemic embolism 65 RE LY ® 65 target lesion revascularization 65 SORT OUT III 65 SPIRIT III 65 biochemical relapse 65 EURIDIS 65 stent thromboses 65 TAXUS Liberte Long 65 stage IIIb IV 65 periprocedural 65 corticosteroid dose 65 nonfatal MI 65 ARCOXIA 65 Val HeFT 65 REYATAZ r arm 65 secondary efficacy endpoint 65 achieved statistical significance 65 CYPHER Stent 65 cisplatin vinorelbine 65 revascularizations 65 Erythropoietic therapies may 65 sirolimus eluting stents 64 patients undergoing CABG 64 locoregional recurrence 64 pCR 64 Stent thrombosis 64 CYPHER ® Stent 64 perioperative mortality 64 carotid endarterectomy CEA 64 relapsed MM 64 workhorse lesions 64 complete cytogenetic response 64 PRADAXA #mg 64 deep venous thromboses 64 segment binary restenosis 64 ID TLR 64 postoperative mortality 64 underwent surgical resection 64 lopinavir r arm 64 recurrent VTE 64 atherothrombotic events 64 CIMZIA ™ 64 TAXUS Stent 64 oral rivaroxaban 64 hsCRP levels 64 biochemical recurrence 64 RECORD1 64 prospectively stratified 64 hemodynamically significant 64 infliximab monotherapy 64 oral diclofenac 63 PSADT 63 PASI scores 63 TRITON TIMI 63 TAXUS ATLAS 63 nadroparin 63 Cypher Stent 63 CIMZIA TM certolizumab pegol 63 sirolimus stent 63 symptomatic intracranial 63 colorectal adenoma 63 somatostatin analog 63 TAXUS 63 CR nPR 63 tirofiban 63 evaluable subjects 63 PREZISTA r arm 63 papillary renal cell carcinoma 63 target vessel revascularization 63 Events MACE 63 XIENCE V stent 63 NEVO 63 nonfatal myocardial infarction 63 aplastic anemia AA 63 ARB telmisartan 63 oxycodone CR 63 histologically confirmed 63 patients undergoing percutaneous 63 ACTEMRA TM 63 histologic subtype 63 HBeAg negative patients 63 everolimus eluting stent 63 microbiologically evaluable 63 lumbar spine BMD 63 adjunctive placebo 63 evaluating mipomersen 63 active comparator 63 retinal vein occlusion induced 63 pravastatin therapy 63 PROMUS Element Stent 63 hip BMD 63 nonrandomized 63 intravascular hemolysis 63 Infusion Reactions Severe 63 unfractionated heparin UFH 63 undetectable HBV DNA 62 coronary revascularization 62 Index CDAI score 62 recurrent malignant glioma 62 TAXUS VI 62 placebo dexamethasone 62 glycated hemoglobin levels 62 ACUITY trial 62 eplerenone 62 hyperphenylalaninemia HPA due 62 TAXUS Liberte Stent 62 myocardial infarction ventricular fibrillation 62 unstable angina UA 62 radiochemotherapy 62 ExTRACT TIMI 62 intravesical therapy 62 dalteparin 62 IIIa inhibitor 62 vessel renarrowing 62 undergone radical prostatectomy 62 PSA nadir 62 intracerebral hemorrhage ICH 62 arterial thromboembolic events 62 prospectively defined 62 naïve HCV 62 teriflunomide 62 receiving INTRON 62 #mg BID [001] 62 ARCALYST ® 62 plus dexamethasone 62 salmeterol fluticasone 62 rosuvastatin #mg 62 STRIDE PD 62 atherothrombotic disease 62 REMINYL ® 62 comparing XIENCE V 62 advanced adenoma 62 multivessel disease 62 achieved CCyR 62 CCyR 62 primary patency 62 confidence interval #.#-#.# 62 intima media thickness 62 EDEMA3 62 receiving golimumab 62 Drug eluting stent 62 pyrexia mucositis sepsis febrile 62 noninferior 62 undergoing coronary artery 62 Flu Cy 62 ug dose 62 intraobserver 62 TAVR 62 perioperative complications 62 lipid lowering agents 62 vertebral fracture 62 mcg albinterferon alfa 2b 62 underwent CABG 62 generalized edema 62 stenoses 62 ENDEAVOR II 62 nonvertebral fractures 62 transfemoral 62 serum aminotransferase levels 62 dose cohort 62 reintervention 62 ejection fractions 62 ATACAND 62 β blockers 62 lymphocytosis 62 placebo controlled clinical 62 serum urate 62 BENICAR HCT 62 Thrombolysis 62 highest tertile 62 Carotid Revascularization Endarterectomy vs. 62 angiographic follow 62 NSTE ACS 62 hemoglobin A1c levels 62 Free Survival PFS 62 abacavir lamivudine 62 certolizumab 62 Coronary Artery Bypass Graft 62 severe exacerbations 62 treatment naive genotype 61 descending thoracic 61 CYPHER R Sirolimus eluting 61 mL/min/#.# m2 61 evaluating tivozanib 61 mL/min/#.# m 2 61 neoadjuvant 61 postoperative complication 61 VELCADE melphalan 61 composite endpoint 61 dosing cohorts 61 venlafaxine XR 61 ACR# responses 61 TEAEs 61 Folfox 61 octreotide LAR 61 probable stent thrombosis 61 dose pravastatin 61 demonstrated clinically meaningful 61 preintervention 61 thromboembolic 61 doxorubicin cyclophosphamide 61 non splenectomized 61 #mg dose [002] 61 elevated ALT 61 RSV hospitalizations 61 SPIRIT FIRST 61 ACR# ACR# 61 coronary stenosis 61 hypercholesterolemic patients 61 clodronate 61 antiretroviral naïve 61 dose Iluvien 61 eptifibatide 61 landmark ATHENA 61 carotid artery stenting CAS 61 mg/m2 dose 61 unresectable HCC 61 IOP lowering 61 placebo controlled Phase III 61 stent binary restenosis 61 angioplasty stenting 61 SPIRIT IV 61 Group RTOG 61 LV dysfunction 61 ADHF 61 urinary N telopeptide 61 grade squamous intraepithelial 61 noninferiority 61 CI #.#-#.# [001] 61 HBeAg seroconversion 61 retrospective cohort 61 humanized interleukin 6 61 q#h 61 doxorubicin docetaxel 61 thromboembolic events 61 dose atorvastatin 61 R# #mg BID 61 keloid scarring 61 antiarrhythmic drug 61 oncologic outcomes 61 recurrent glioblastoma multiforme 61 undergoing coronary angiography 61 mg administered orally 61 lispro 61 atheroma volume 61 serum triglycerides 61 CC genotype 61 neutropenia dehydration dyspnea 61 prednisone prednisolone plus 61 receiving SIMPONI 61 pT3 61 intracranial atherosclerosis 61 -#.# log# copies mL 61 nonfatal myocardial infarction MI 61 atherogenic dyslipidemia 61 carotid artery blockage 61 piperacillin tazobactam 61 CRp 61 nonfatal stroke 61 coronary revascularization procedures 61 CYPHER ® 61 rebleeding 61 QTcF 61 macrovascular events 61 subtrochanteric 61 preoperative chemotherapy 61 refractory ischemia 61 visceral metastases 61 cerebrovascular events 61 multicentric 61 mcg BID 61 deCODE AF TM 61 CVD mortality 61 cardiovascular hospitalizations 61 myocardial infarction stroke 61 parathyroid carcinoma 61 thromboembolic complications 61 completely resected 61 Secondary endpoints included 61 NATRECOR ® 61 onset diabetes mellitus 61 squamous histology 61 COPD exacerbation 61 TAXUS Liberté stent 61 artery stenosis 61 irbesartan 61 nonfasting triglyceride levels 61 nonobstructive CAD 61 highly emetogenic 61 Unstable Angina 61 anti arrhythmic drug 61 tolvaptan 60 mg QD 60 plus gemcitabine 60 myocardial infarction MI 60 ximelagatran 60 FFR guided 60 cilostazol 60 NMIBC 60 sirolimus eluting stent 60 8mg/kg 60 fluticasone salmeterol 60 recurrent ischemia 60 hepatic resection 60 Secondary endpoints include 60 MoxDuo TM IR 60 endoscopic remission 60 placebo PBO 60 methotrexate monotherapy 60 peripheral arterial occlusive disease 60 dosing cohort 60 paroxysmal AF 60 recurrent venous thromboembolism 60 paclitaxel eluting 60 pT2 60 glycoprotein IIb IIIa inhibitor 60 serum phosphate 60 candidemia 60 radiotherapy RT 60 prespecified 60 HER2 expression 60 elevated LDH 60 % CI #.#-#.# [007] 60 Complication rates 60 nephron sparing surgery 60 thrombocytopenic 60 biliary tract cancer 60 cardiovascular hospitalization 60 liver histology 60 recurrent DVT 60 mcg kg REBETOL 60 sUA 60 carotid stenosis 60 pain palliation 60 HbA1C levels 60 % CI #.#-#.# [003] 60 desvenlafaxine succinate 60 Patency 60 extracapsular extension 60 nicardipine 60 Kaplan Meier analysis 60 treatment naïve genotype 60 HbA 1c levels 60 Response Evaluation Criteria 60 CYPHER R Stent 60 PAOD 60 statin monotherapy 60 Ramipril 60 HeFH 60 CTEPH 60 postoperative AF 60 transarterial 60 neutrophil counts 60 liver resection 60 relapsing remitting MS RRMS 60 paclitaxel eluting stent 60 dapagliflozin plus 60 INCB# [003] 60 MCyR 60 heFH 60 bypass graft CABG surgery 60 oral FTY# 60 azilsartan medoxomil 60 coronary interventions 60 Xelox 60 repeat paracentesis 60 landmark ATHENA trial 60 overt hepatic encephalopathy HE 60 PRIMO CABG 60 leiomyomas 60 thyrotropin levels 60 baseline HbA1c 60 onset atrial fibrillation 60 adenoma recurrence 60 clinicopathological features 60 mcg QD 60 plus methotrexate 60 comparator arm 60 discontinuations due 60 TAXUS Element Stent 60 mitoxantrone plus 60 5-FU/LV 60 log# IU mL 60 silent ischemia 60 #.#mg/dL 60 hepatic metastases 60 TAXUS stent 60 moderate renal impairment 60 bifurcated lesions 60 statistically significant p = 60 noncarriers 60 mg p = 60 malignancy HCM 60 radical nephrectomy 60 GORE TAG Device 60 prospective multicenter study 60 oral antidiabetic medication 60 adjunctive ABILIFY 60 annualized relapse 60 attain statistical significance 60 pericardial effusion 60 tapentadol ER 60 DU #b 60 MADRS score 60 HIV HCV coinfected 60 prospective multicenter randomized 60 ischemic lesions 60 venous thromboembolic disease 60 irinotecan cisplatin 60 undergoing percutaneous coronary 60 steroid refractory 60 endobronchial 60 DAS# remission 60 NATRECOR R 60 coronary revascularisation 60 FluCAM arm 60 splenectomized 60 stroke myocardial infarction 60 NEVO ™ 60 advanced hepatocellular carcinoma 60 FOLFOX4 60 HBeAg positive patients 60 MAGE A3 ASCI 60 aspirin clopidogrel 60 catheter occlusion 60 reduce serum phosphate 60 neurologic progression 60 trials RCTs 60 cytogenetic response 60 underwent percutaneous coronary 60 AA Amyloidosis 60 plus prednisone 60 Postoperative complications 60 Percutaneous Coronary Intervention 60 NPH insulin 60 Randomized Evaluation 60 multicenter Phase III 60 metformin sulfonylurea 60 de novo lesions 60 symptomatic aortic stenosis 60 metaglidasen 60 liver metastasis 60 stent restenosis 60 microbiological eradication 60 posaconazole 60 nonmetastatic 60 stable angina 60 postoperative morbidity 60 Radical prostatectomy 60 thetreatment 60 HCV RESPOND 2 60 tolterodine ER 60 dyslipidaemia 60 unresectable tumors 60 metastatic GIST 60 receiving XGEVA 60 metformin monotherapy 60 CYT# potent vascular disrupting 60 atherothrombosis 60 Bare Metal Stents 60 peripheral sensory neuropathy 60 Angiographic 60 GG genotype 60 acute STEMI 60 q8h 60 primary percutaneous coronary 60 % Confidence Interval 60 systolic dysfunction 59 vaso occlusive crisis 59 vitreous floaters 59 tipranavir r 59 graft occlusion 59 pretreatment serum 59 Pivotal Phase 59 skeletal metastases 59 hemoglobin A1c HbA1c 59 anthracycline taxane 59 Ishak fibrosis score 59 rimonabant #mg 59 ertapenem 59 sirolimus eluting 59 oral allopurinol 59 echocardiographic parameters 59 del 5q MDS 59 zotarolimus 59 percutaneous transluminal coronary angioplasty 59 Crohn Disease Activity 59 rFVIIa 59 haematologic 59 Arch Intern Med 59 daily subcutaneous injections 59 severe neutropenia 59 DAS# CRP 59 neutropenic sepsis 59 weekly CSBMs 59 headache nasopharyngitis 59 perioperative morbidity 59 p = ns 59 transurethral resection 59 microvascular complications 59 carboplatin chemotherapy 59 controlled multicenter 59 statistically significant efficacy 59 fractional shortening 59 intracerebral hemorrhages 59 extracranial 59 lintuzumab SGN 59 renal cortical 59 Tasigna prolongs 59 null responder HCV 59 PRECiSE 59 ABC/3TC 59 dose clopidogrel 59 Zemplar Capsules 59 MIST II 59 gout flares 59 Multidetector CT 59 surgically resected 59 ARIXTRA 59 pegylated liposomal doxorubicin 59 Venous thromboembolism 59 novel VDA molecule 59 demonstrated antitumor activity 59 leucopenia 59 Coronary artery bypass graft 59 #mg/day [001] 59 Febrile neutropenia 59 multicentre randomized 59 noninvasive outpatient 59 A1c levels 59 undergoing elective percutaneous 59 LHRH receptor positive 59 NYHA Class III 59 serum clusterin levels 59 mmHg diastolic 59 resuscitated cardiac arrest 59 achieved PASI 59 hormone receptor negative 59 micafungin 59 BARACLUDE ® 59 sumatriptan naproxen sodium 59 Cimzia TM 59 gross hematuria 59 low dose Iluvien 59 carotid revascularization 59 CLARITY study 59 melphalan prednisone 59 transplantation HCT 59 chlorambucil 59 glycosylated hemoglobin levels 59 EDARBI 59 cyclophosphamide methotrexate 59 p = #.# [003] 59 left ventricular dysfunction 59 CABG surgeries 59 Acute Myocardial Infarction 59 TAXUS V 59 serum estradiol 59 confirmed CCyR 59 periprocedural MI 59 acute myocardial infarction AMI 59 REYATAZ r 59 clinically meaningful reductions 59 hour bronchodilation 59 CI -#.# 59 drug eluting stent implantation 59 Combination therapy 59 inhospital 59 complete cytogenetic 59 Coronary artery bypass grafting 59 insulin detemir 59 colorectal adenomas 59 evaluable 59 Major Adverse Cardiac 59 fluvastatin 59 linaclotide treated 59 recurrent metastatic 59 endometrial thickness 59 LV ejection fraction 59 intracranial stenosis 59 induce orthostatic hypotension 59 normotensive 59 chronic thromboembolic pulmonary 59 APPRAISE 59 NIHSS score 59 p ≤ 59 maximally tolerated dose 59 deferiprone 59 pimecrolimus cream 59 ENDEAVOR IV 59 elevated troponin 59 Transcatheter aortic valve implantation 59 intracranial hemorrhage ICH 59 Index CDAI 59 metastatic hormone refractory 59 DLTs 59 dysuria 59 CIMZIA TM 59 Acute Ischemic Stroke 59 proximal DVT 59 luminal diameter 59 Edge STudy 59 infarct size 59 RE LY 59 candesartan cilexetil 59 triglyceride concentrations 59 cerebral vasospasm 59 Non inferiority 59 Randomized Study 59 Hb A1C 59 heavily pretreated 59 prospectively evaluated 59 BENICAR 59 systolic hypertension 59 distal embolization thrombus formation 59 Pharmacokinetic parameters 59 CHD CVD 59 imipenem 59 T1c 59 BRIM2 59 hepatocellular carcinomas 59 primary hypercholesterolemia 59 complement inhibitor eculizumab 59 N Engl J 59 death dissection perforation 59 EDEMA3 trial 59 coronary stenting 59 acute myocardial infarctions 59 TG MV 59 advanced adenomas 59 TAXUS Express Atom Stent 59 carboplatin paclitaxel 59 EVEREST II 59 Acetate Rectal Suppositories 59 Doxil ® 59 bivalirudin monotherapy 59 ABSORB trial 59 postoperative bleeding 59 dose dexamethasone 59 acyclovir Lauriad R 59 RAPTIVA 59 Renal Cell Carcinoma RCC 59 ROCKET AF 59 FOLPI 59 lanthanum carbonate 59 apolipoprotein B 59 protein excretion 59 stent DES 59 infusional 59 CRESTOR #mg 59 ELBW infants 59 Hazard Ratio = 59 HF hospitalization 59 prospective multicentre 59 retrospectively analyzed 59 multicenter randomized placebo controlled 59 median CD4 59 gadolinium enhancing 59 DAPT 59 Tarceva TM 59 NYHA functional class 59 de novo coronary artery 59 apnea hypopnea index 59 recurrent GBM 59 resistant hormone refractory 59 Oral Fingolimod 59 multicentre 59 allogeneic HSCT 59 HBeAg 59 NNT = 59 intracerebral haemorrhage 59 hepatorenal syndrome 59 Raptiva r 59 paroxysmal atrial fibrillation 59 J Am Coll 59 antiplatelet agent 59 recurrent myocardial infarction 59 EGFR mutation positive 59 % CI #.#-#.# [008] 59 dyslipidemia hypertension diabetes 59 Hypotension 59 PEGINTRON TM 58 % CI #.#-#.# [005] 58 neointimal hyperplasia 58 TAXUS TM 58 adult chronic ITP 58 Amrubicin 58 multicentre prospective 58 angina myocardial infarction 58 percutaneous intervention 58 subanalysis 58 multivariable adjusted 58 neurologic complications 58 obstructive coronary artery 58 RLAI 58 CHAMPION PCI 58 TAXUS IV 58 LEXIVA r 58 lymphadenectomy 58 revascularization procedures 58 BMS p = 58 MMSE score 58 atorvastatin #mg 58 secondary endpoint 58 lowest tertile 58 UA NSTEMI 58 briakinumab 58 myocardial infarctions 58 nonvertebral fracture 58 alanine aminotransferase 58 HORIZONS AMI trial 58 virological response 58 multivariate Cox 58 hematologic toxicity 58 PROMUS Element 58 prostate carcinoma 58 invasive ductal 58 plus COPEGUS 58 HAM D# scores 58 Vicinium TM 58 resectable pancreatic cancer 58 tumor necrosis 58 recurrent atrial fibrillation 58 prednisone prednisolone 58 ULORIC 58 endarterectomy 58 retinal vein occlusion 58 FOLFOX6 chemotherapy regimen 58 Dextofisopam 58 coronary intervention 58 fibrinolysis 58 macroalbuminuria 58 salpingo oophorectomy 58 chronic periodontitis 58 ST elevation myocardial 58 mg kg dose 58 abdominal pain abdominal discomfort 58 glycated hemoglobin HbA1c 58 cardiovascular mortality 58 left ventricular systolic 58 grade cervical dysplasia 58 XIENCE V Stent System 58 euthyroid 58 EDSS scores 58 foveal thickness 58 valvular disease 58 GOUT 58 elotuzumab 58 refractory NSCLC 58 radical retropubic prostatectomy 58 Octreolin 58 gemcitabine carboplatin 58 thrombus aspiration 58 Castration Resistant Prostate Cancer 58 Thal Dex 58 baseline serum creatinine 58 activated partial thromboplastin 58 resected pancreatic cancer 58 induced macular edema 58 biventricular repair 58 coronary revascularizations 58 INSPIRE Trial Phase III 58 duplex ultrasonography 58 serum calcium levels 58 cystectomy 58 mediastinal 58 serum urate levels 58 prospective multicenter 58 MGd 58 CTAP# Capsules 58 IFN alfa 58 Ophena TM 58 SYNTAX trial 58 beta blockers ACE inhibitors 58 BR.# 58 Hazard Ratio 58 HBeAg negative 58 acute coronary syndromes ACS 58 HOMA IR 58 postop 58 Ranolazine 58 variceal bleeding 58 inflammatory lesions 58 failure TVF 58 thromboembolism 58 Zometa hazard 58 ViaDerm hPTH #-# 58 dacarbazine DTIC 58 intraventricular hemorrhage 58 RAPAFLO R 58 malignant neoplasm 58 homozygous familial hypercholesterolemia 58 sustained virological response 58 renal tumors 58 dose statin therapy 58 chemoradiation therapy 58 cardiac dysfunction 58 receptor tyrosine kinase inhibitor 58 ALT elevation 58 multicenter randomized controlled 58 BRIM3 58 hemodialysis patients 58 bone marrow reticulin deposition 58 pyelonephritis 58 pamidronate 58 salmeterol HFA MDI 58 TAXUS Express 58 UPPP 58 atrioventricular block 58 Elitek 58 laparoscopically assisted 58 antithrombotic therapy 58 Nephrol Dial Transplant 58 retrospective observational study 58 severe renal impairment 58 pretest probability 58 liver transplant recipients 58 receiving PEGINTRON 58 fasting plasma glucose FPG 58 conjunctival hyperemia 58 response CCyR 58 parecoxib 58 F FDG PET 58 CYPHER ® Sirolimus eluting 58 serum phosphorous 58 ENDEAVOR III 58 Gastrointestinal Stromal Tumors 58 symptomatic carotid stenosis 58 achieved sustained virological 58 Epanova 58 plus GP IIb 58 TMC# r 58 confirmed thrombotic cardiovascular 58 NEVO RES 58 multicenter prospective 58 Percutaneous Transluminal Coronary Angioplasty 58 aminotransferase elevations greater 58 dosage regimens 58 #mg doses [002] 58 serum creatinine levels 58 achieving PASI 58 idraparinux 58 ACE inhibitor ramipril 58 nonischemic 58 P = .# 58 arteriography 58 herpetic keratitis 58 double blinded randomized 58 localized renal 58 HCV SPRINT 58 debulking surgery 58 statistical significance p 58 full thickness plication 58 IMiDs ® compound 58 colorectal carcinoma 58 LymphoStat B belimumab 58 non constipating irritable 58 symptomatic BPH 58 Ischemic 58 experienced virologic failure 58 circulating EPCs 58 Lupuzor ™ 58 NYHA class 58 undergoing radical cystectomy 58 progression TTP 58 Dapagliflozin 58 timepoints 58 eszopiclone 58 hepatectomy 58 nondepressed 58 docetaxel Taxotere ® 58 FDG-PET/CT 58 HealthGrades analyzed 58 Carotid endarterectomy 58 ruboxistaurin 58 coronary artery bypass grafts 58 null responder 58 relapsed refractory multiple myeloma 58 underwent coronary angiography 58 elevated triglyceride levels 58 sunitinib malate 58 interferon beta therapy 58 concurrent chemoradiation 58 ANCHOR trial 58 febrile neutropenia 58 subarachnoid hemorrhage SAH 58 β blocker 58 parous women 58 Acute Decompensated Heart Failure 58 amoxicillin clavulanate 58 SUVmax 58 operable breast cancer 58 Scale EDSS 58 ezetimibe simvastatin 58 NNRTI resistance 58 intraoperative complications 58 J Clin Oncol 58 VADT 58 clinically localized prostate 58 aldosterone antagonist 58 oral antidiabetic drugs 58 nonsignificant 58 mediated dilation 58 colorectal liver metastases 58 nab paclitaxel 58 symptomatic DVT 58 intracoronary 58 iniparib BSI 58 revascularization procedure 58 Atherosclerotic 58 FROVA 58 forodesine 58 Subgroup analysis 58 ventricular tachyarrhythmia 58 locoregional disease 58 prostate TURP 58 carotid IMT 58 p = NS 58 non inferiority 58 subthreshold depression 58 invasive candidiasis 58 RANK Ligand inhibitor 58 chronic prostatitis chronic 58 Fractional Flow Reserve 58 DES implantation 58 Sirolimus eluting Coronary Stent 58 + PH# 58 polypoid 58 gadolinium enhanced 58 elevated hsCRP 58 albumin excretion rate 58 #.#ng/ml 58 mediastinitis 58 colesevelam HCl 58 stage IIIB 58 ACCORD Lipid 58 VATS lobectomy 58 stable angina pectoris 58 decompensated liver disease 58 efficacy endpoint 58 virologic breakthrough 58 salmeterol fluticasone propionate 58 CATIE AD 58 sustained ventricular tachycardia 58 Ceplene/IL-2 58 lopinavir r 58 GP IIb IIIa inhibitor 58 carotid artery stenosis 58 antiplatelet drugs 58 thrombotic events 58 #rd Annual CTRC 58 MitraClip device 58 -#.# mg dL [001] 58 cinacalcet 58 wedge resection 58 thiazide diuretic 58 refractory metastatic colorectal cancer 58 umol L 58 cisplatin gemcitabine 58 Solazed

Back to home page